Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa

Canada Communicable Disease Report = Relevé Des Maladies Transmissibles Au Canada
G J GermanM R Mulvey

Abstract

The goal of this document was to provide Canadian laboratories with a framework for consistent reporting and monitoring of multidrug resistant organisms (MDRO) and extensively drug resistant organisms (XDRO) for common gram-negative pathogens. This is the final edition of the interim recommendations, which were modified after one year of broad consultative review. This edition represents a consensus of peer-reviewed information and was co-authored by the Canadian Public Health Laboratory Network and the Canadian Association of Clinical Microbiology and Infectious Diseases. There are two main recommendations. The first recommendation provides standardized definitions for MDRO and XDRO for gram-negative organisms in clinical specimens. These definitions were limited to antibiotics that are commonly tested clinically and, to reduce ambiguity, resistance (rather than non-susceptibility) was used to calculate drug resistance status. The second recommendation identifies the use of standardized laboratory reporting of organisms identified as MDRO or XDRO. Through the broad consultation, which included public health and infection prevention and control colleagues, these definitions are ready to be applied for policy development. Both a...Continue Reading

References

Aug 19, 2007·BMC Infectious Diseases·Homer C TienAndrew Simor
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Nov 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R LeclercqG Kahlmeter
Mar 9, 2012·The Journal of Antimicrobial Chemotherapy·L F MatasejeUNKNOWN Canadian Nosocomial Infection Surveillance Program

❮ Previous
Next ❯

Citations

Sep 11, 2019·The Journal of Antimicrobial Chemotherapy·Melissa G McCrackenUNKNOWN Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD
Mar 4, 2020·Antimicrobial Agents and Chemotherapy·Alireza EshaghiSamir N Patel
Oct 13, 2018·The Journal of Antimicrobial Chemotherapy·David A BoydUNKNOWN Canadian Nosocomial Infection Surveillance Program
Mar 11, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Nadezhda K FursovaNikolay V Volozhantsev
Aug 12, 2021·The Journal of Antimicrobial Chemotherapy·James A KarlowskyGeorge G Zhanel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.